甲状腺乳头状癌组织中酪氨酸激酶受体第16外显子基因突变情况及意义  

Mutation of RET exon 16 in the papillary thyroid cancer and clinical significance

作　　者：濮亚斌[1] 李刚强[1] 

机构地区：[1]中国人民解放军第四五五医院,上海200052

出　　处：《山东医药》2014年第48期22-23,I0017,共3页Shandong Medical Journal

基　　金：上海市长宁区卫生和计划生育委员会科研项目(20134Y16001)

摘　　要：目的检测甲状腺乳头状癌(PTC)患者酪氨酸激酶受体(RET)第16外显子基因突变情况,并探讨其临床意义。方法采用直接测序的方法检测60例PTC组织(观察组)和其中20例癌旁正常组织(对照组)中的RET第16外显子基因,并分析其与PTC患者年龄、性别、肿瘤大小、肿瘤类型、淋巴结转移及TNM分期的关系。结果观察组中,11例(18.3%)出现RET基因第16外显子基因突变,对照组未见上述突变;两组突变率比较,P<0.05。RET基因第16外显子突变与PTC患者的年龄、性别、肿瘤大小、肿瘤类型、淋巴结转移及TNM分期均无关(P均>0.05)。结论 PTC患者RET第16外显子基因突变率升高,可能与PTC的发生有关。Objective To investigate the mutation of RET exon 16 in papillary thyroid cancer and to discuss its clinical significances .Methods DNA sequencing was performed to detect the mutation in 60 papillary thyroid cancer （ observation group） and twenty normal control group .The mutation were respectively observed in clinical and pathological features of pa -pillary thyroid cancer group .Results In the observation group , 11 cases were found RET exon 16 point mutation that was 918 bases existing C replacement T , no mutation of RET exon 16 was found in control group , P〈0.05.The mutation of RET exon 16 was not related to clinical and pathological features in observation group （all P〉0.05）.Conclusion The mutation of RET exon 16 in papillary thyroid cancer patients increased , which was involved in carcinogenesis .

关 键 词：甲状腺肿瘤 乳头状 酪氨酸激酶受体 基因突变 

分 类 号：R736.1[医药卫生—肿瘤]